
Cleavage site-directed antibodies revealed that ADAM10 sheds the prion protein (PrP) at tyrosine 226 in humans. This shedding, involving a GPI-anchored glycoprotein, impacts neurodegenerative diseases. Researchers identified the shed form of PrP (sPrP) using specific antibodies in human tissues and animal models. sPrP relocalizes from diffuse patterns to misfolded protein deposits in conditions like Alzheimer's and prion diseases. The study demonstrates that PrP-binding ligands can stimulate PrP shedding, presenting new therapeutic avenues. These findings highlight the role of PrP shedding in neurodegeneration, providing insights and research tools for future studies.
Like
Save
Share